CA2389851A1 - Human igm antibodies to chemokine receptors - Google Patents

Human igm antibodies to chemokine receptors Download PDF

Info

Publication number
CA2389851A1
CA2389851A1 CA002389851A CA2389851A CA2389851A1 CA 2389851 A1 CA2389851 A1 CA 2389851A1 CA 002389851 A CA002389851 A CA 002389851A CA 2389851 A CA2389851 A CA 2389851A CA 2389851 A1 CA2389851 A1 CA 2389851A1
Authority
CA
Canada
Prior art keywords
igm
antibodies
receptors
cells
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002389851A
Other languages
English (en)
French (fr)
Inventor
Peter I. Lobo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2389851A1 publication Critical patent/CA2389851A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
CA002389851A 1999-11-14 2000-11-14 Human igm antibodies to chemokine receptors Abandoned CA2389851A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US43969099A 1999-11-15 1999-11-15
US09/439,690 1999-11-15
US09/684,813 2000-10-10
US09/684,813 US6610834B1 (en) 1998-11-18 2000-10-10 Human IgM antibodies to chemokine receptors
PCT/US2000/031051 WO2001035980A1 (en) 1999-11-14 2000-11-14 HUMAN IgM ANTIBODIES TO CHEMOKINE RECEPTORS

Publications (1)

Publication Number Publication Date
CA2389851A1 true CA2389851A1 (en) 2001-05-25

Family

ID=27032133

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002389851A Abandoned CA2389851A1 (en) 1999-11-14 2000-11-14 Human igm antibodies to chemokine receptors

Country Status (8)

Country Link
US (1) US6610834B1 (https=)
EP (1) EP1231930B1 (https=)
JP (1) JP2003516940A (https=)
AT (1) ATE464909T1 (https=)
AU (1) AU1599601A (https=)
CA (1) CA2389851A1 (https=)
DE (1) DE60044259D1 (https=)
WO (1) WO2001035980A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080118522A1 (en) * 1998-11-18 2008-05-22 Lobo Peter I Naturally occuring IgM antibodies that bind lymphocytes
US20030099645A1 (en) * 2000-10-10 2003-05-29 Lobo Peter Isaac Naturally occuring IgM antibodies that bind to membrane receptors on lymphocytes
CN1997893A (zh) * 2004-04-16 2007-07-11 健泰科生物技术公司 抗体测定法
EP1817054A1 (en) * 2004-12-01 2007-08-15 Peter I. Lobo Naturally occuring igm antibodies that bind lymphocytes
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
JP2009531283A (ja) 2006-02-02 2009-09-03 アラーガン、インコーポレイテッド 眼系疾患の処置のための組成物および方法
TW200817438A (en) * 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
EP2054086A1 (en) 2006-08-17 2009-05-06 F. Hoffmann-Roche AG A conjugate of an antibody against ccr5 and an antifusogenic peptide
CN101516914A (zh) 2006-09-29 2009-08-26 霍夫曼-拉罗奇有限公司 针对ccr5的抗体及其应用
US20090143288A1 (en) * 2007-03-13 2009-06-04 Roche Palo Alto Llc Peptide-complement conjugates
GB201002238D0 (en) 2010-02-10 2010-03-31 Affitech As Antibodies
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
WO2017140794A1 (en) * 2016-02-16 2017-08-24 Celltrend Gmbh Anti-cxc chemokine receptor antibodies and c-x-c chemokines for the diagnosis of autoimmune disease and graft-versus-host disease
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8605316D0 (en) * 1986-03-04 1986-04-09 Royal Free Hosp School Med Immunosuppression
US5215913A (en) * 1987-11-30 1993-06-01 Roger Williams General Hospital IgG-1 human monoclonal antibody reactive with an HIV-1 antigen and methods of use
US5606026A (en) * 1988-03-25 1997-02-25 The Institute For Human Genetics And Biochemistry Natural human IgM antibodies immunoreactive with the Tat protein of HIV-1
ES2156149T3 (es) * 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5961976A (en) * 1996-06-03 1999-10-05 United Biomedical, Inc. Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
US5994515A (en) * 1996-06-25 1999-11-30 Trustees Of The University Of Pennsylvania Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same
WO1997049424A1 (en) * 1996-06-25 1997-12-31 The Trustees Of The University Of Pennsylvania Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same
US6057102A (en) * 1996-08-08 2000-05-02 The Aaron Diamond Aids Research Center HIV coreceptor mutants
US6100387A (en) 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US6312689B1 (en) * 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
JP2000229997A (ja) * 1999-02-10 2000-08-22 Nissui Pharm Co Ltd 環状ペプチド及びエイズワクチン

Also Published As

Publication number Publication date
WO2001035980A1 (en) 2001-05-25
US6610834B1 (en) 2003-08-26
DE60044259D1 (de) 2010-06-02
EP1231930B1 (en) 2010-04-21
EP1231930A1 (en) 2002-08-21
JP2003516940A (ja) 2003-05-20
ATE464909T1 (de) 2010-05-15
EP1231930A4 (en) 2005-07-27
AU1599601A (en) 2001-05-30

Similar Documents

Publication Publication Date Title
AU724037B2 (en) Antibodies binding to monocyte chemoattractant protein 1 (MCP-1) receptor (CCR2)
ES2225820T3 (es) Receptor cd40cr y ligandos del mismo.
US6610834B1 (en) Human IgM antibodies to chemokine receptors
Moreau et al. Practical considerations for the use of daratumumab, a novel CD38 monoclonal antibody, in myeloma
JP5394916B2 (ja) Ｎｋｇ２ｄの調節方法
AU2014372657B2 (en) Therapeutic methods and compositions
US20050220787A1 (en) Naturally occuring IgM antibodies that bind to lymphocytes
US20030099645A1 (en) Naturally occuring IgM antibodies that bind to membrane receptors on lymphocytes
van Delft et al. Antagonizing FcαR1 (CD89) as treatment in IgA-mediated chronic inflammation and autoimmunity
AU766882B2 (en) Product and method for treatment of conditions associated with receptor-desensitization
Warren et al. Convergence between CD98 and integrin‐mediated T‐lymphocyte co‐stimulation
Abdel-Salam et al. Autoantibodies to neutrophil cytoplasmic antigens (ANCA) do not bind to polymorphonuclear neutrophils in blood
Zhu et al. Suppression of allo-human leucocyte antigen (HLA) antibodies secreted by B memory cells in vitro: intravenous immunoglobulin (IVIg) versus a monoclonal anti-HLA-E IgG that mimics HLA-I reactivities of IVIg
Silvestris et al. Cross-linking of Fas By Antibodies to a Peculiar Domain of gp120 V3 Loop Can Enhance T Cell Apoptosis in HIV-1–infected Patients
Gurevich‐Shapiro et al. Intravenous immunoglobulin–induced acute thrombocytopenia
US20080118522A1 (en) Naturally occuring IgM antibodies that bind lymphocytes
JP2007505141A (ja) Ｃｄ９９アンタゴニストを用いる慢性関節リウマチの処置
JP2019507102A (ja) 抗−ヒトｉｌ−３抗体、ｉｌ−３の高められた発現又はレベルに関連する疾患又は機能障害へのそれらの使用、及びヒトｉｌ−３の検出方法へのそれらの使用
US20080112950A1 (en) Naturally occurring IgM antibodies that bind lymphocytes
KR20220062037A (ko) 오말리주맙을 사용한 치료 방법
WO2006059176A1 (en) Naturally occuring igm antibodies that bind lymphocytes
von Wardenburg et al. Engineered Bi-Specific AChR CAAR T Cells for Selective Elimination of Myasthenia Gravis B Cells
Hack Characterization of anti-platelet factor 4 antibodies and their persistence in vaccine-induced immune thrombotic thrombocytopenia
JP3715313B2 (ja) ヒト細胞接着性タンパク質ａａｍｐ‐１及びその利用
Hildreth et al. Production and characterization of monoclonal antibodies against pigtailed macaque (Macaca nemestrina) cell adhesion molecules

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued